Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

LSA MEETING: Thalidomide Promising For Multiple Myeloma Patients LITTLE ROCK, AR -- Sept. 28, 1998 -- Encouraging new data on Celgene Corp.’s Thalidomid™ (thalidomide) for the treatment of multiple myeloma, the second most common blood cancer, was presented this weekend at a meeting of the Leukemia Society of America in Washington, D.C. Jayesh Mehta, M.D., of the Arkansas Cancer Research Center (ACRC), presented the results of the study of 26 patients with end state refractory (non-responsive) multiple myeloma. The disease ceased to progress in nearly 60 percent of patients who received thalidomide, with some patients experiencing a reduction in tumour growth and three patients approaching complete response. Ninety-two percent of the patients in the study had received bone marrow transplants, with close to 70 percent receiving this treatment at least twice. In all cases, bone marrow transplantation had failed as a therapy. Preliminary data from an expanded study of 125 multiple myeloma patients, are consistent with the findings in the initial study of 26 patients. The side effects of the drug were consistent with those seen in other thalidomide clinical studies. "The results of this study are extraordinary -- especially when one considers that these patients had failed all other therapy," Dr. Mehta said. "We are particularly encouraged that initial results of our expanded study involving over 120 patients appear to be consistent with our preliminary findings." Studies are continuing at the ACRC to evaluate the potential role of thalidomide in the treatment of multiple myeloma. According to the Leukemia Society of America, 13,800 new cases of multiple myeloma will be reported this year and approximately 11,300 people will die from the disease this year. Related Links: Thalidomide, Celgene Corp. E-mail this page to a friend or colleague! To print, use this version